Narender Katakam, Sridevi Durgaraju
BACKGROUND This study evaluated the effect of treatment of many oral hypoglycaemic agents on bone metabolism in patients with type 2 diabetes mellitus and occurrence of osteoporosis. MATERIALS AND METHODS This cross-sectional study was conducted in Department of General Medicine of Chalmeda Ananda Rao Institute of Medical Sciences, Karimnagar, Telangana, between January 2015 to February 2017. RESULTS 250 patients were screened for this study. From these, 50 patients with T2DM were included in the study who were satisfying the inclusion criteria. Age in years of patients with T2DM was 50.5±4.8 and in control group, age in years was 50.8±2.5. BMI in kg/m2 in patients with T2DM was 25.6±6.9, in control group, BMI was 28.5±3.88 kg/ m2. Median duration of menopause was 5 in patients with T2DM and it was 5 in control group. There were more women in both the groups i.e. in patients with T2DM, 36/50; in control group, 35/50. The mean duration of T2DM in the study group was 6.09±1.9 years; mean HbA1C was 8.0±1%. 15 patients were using either TZD alone or in combination with other OHA, the remaining 35 were using other OHA alone or in combination. Overall BMD was in postmenopausal was less significantly at the neck of femur compared to lumbar spine in anterior–posterior view. The BMD in g/cm2 and z-scores at NOF and LSAP were comparable between the study group and control group. There was no significant difference in the presence of BMD, osteopenia and osteoporosis between both the groups. One-way ANOVA did not show any significant difference between BMD NOF and LSAP, T-scores at level of NOF and LSAP, Z-scores at level of NOF and LSAP on comparing between patients with T2DM treated with TZD, patients with T2DM treated with other OHA and control group. CONCLUSION For a period of two years or more, the present study shows that the use of OHA does not significantly affect the BMD in patients with T2DM.
